Financial Report: Genzyme

Genzyme

4Q Revenue: $854.2 million (+17%)

4Q Earnings: $209 million (+29%)

FY Revenue: $3.2 billion (+17%)

FY Loss: $16.8 million (earnings were $441.5 million FY2005)

Comments: Myozyme for Pompe disease was launched in Europe and the U.S. in 2Q2006, and sales for the year were $59 million. Fabrazyme sales were $359 million and Cerezyme sales were $1 billion for the year. Sales of Renagel were $515 million and sales of Synvisc were $234 million for the year. FY Loss includes a charge of $552.9 million related to in-process R&D acquired from AnorMED. R&D expenses in the quarter were $166.4 million, up 20% and were $650 million for the year, up 29%.